Roche is dropping out of its partnership with Maxygen to develop a therapy for uncontrolled bleeding in an emergency setting. The company expressed its disappointment at the decision, but added that the two drug companies would continue to work together on programs for hepatitis C and B.
- read this press release [1]
- check out the AP report [2] on the undoing of the deal
Related Article:
Roche to boost R&D spend, reorganize research. Report [3]
Links:
[1] http://www.fiercebiotech.com/node/6033
[2] http://www.businessweek.com/ap/financialnews/D8NRHACG1.htm
[3] http://www.fiercebiotech.com/story/roche-to-boost-rd-spend-reorganize-research/2007-02-05